Emily Wiecek, O.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vision, Binocular | 4 | 2024 | 226 | 1.990 |
Why?
|
Vision Disorders | 5 | 2021 | 1088 | 1.250 |
Why?
|
Anisometropia | 1 | 2024 | 17 | 0.930 |
Why?
|
Visual Acuity | 6 | 2024 | 2672 | 0.920 |
Why?
|
Amblyopia | 2 | 2024 | 150 | 0.890 |
Why?
|
Visual Fields | 2 | 2024 | 1062 | 0.850 |
Why?
|
Myopia | 2 | 2024 | 253 | 0.850 |
Why?
|
Convergence, Ocular | 1 | 2021 | 26 | 0.740 |
Why?
|
Refractive Errors | 1 | 2022 | 147 | 0.700 |
Why?
|
Strabismus | 1 | 2024 | 317 | 0.670 |
Why?
|
Pattern Recognition, Visual | 2 | 2014 | 823 | 0.580 |
Why?
|
Vision Tests | 2 | 2014 | 161 | 0.570 |
Why?
|
Retinopathy of Prematurity | 1 | 2022 | 439 | 0.570 |
Why?
|
Macular Degeneration | 2 | 2014 | 1007 | 0.520 |
Why?
|
Vision, Monocular | 1 | 2014 | 71 | 0.460 |
Why?
|
Scotoma | 1 | 2012 | 130 | 0.380 |
Why?
|
Eye Movements | 2 | 2021 | 511 | 0.360 |
Why?
|
Retinal Diseases | 1 | 2014 | 705 | 0.310 |
Why?
|
Mydriatics | 2 | 2024 | 67 | 0.260 |
Why?
|
Axial Length, Eye | 1 | 2024 | 35 | 0.240 |
Why?
|
Epiretinal Membrane | 2 | 2014 | 73 | 0.230 |
Why?
|
Depth Perception | 1 | 2024 | 94 | 0.220 |
Why?
|
Geographic Atrophy | 2 | 2014 | 91 | 0.220 |
Why?
|
Refraction, Ocular | 1 | 2024 | 184 | 0.220 |
Why?
|
Wet Macular Degeneration | 2 | 2014 | 162 | 0.200 |
Why?
|
Contrast Sensitivity | 2 | 2014 | 253 | 0.200 |
Why?
|
Accommodation, Ocular | 1 | 2021 | 47 | 0.180 |
Why?
|
Fovea Centralis | 1 | 2021 | 126 | 0.180 |
Why?
|
Intravitreal Injections | 1 | 2022 | 385 | 0.170 |
Why?
|
Models, Statistical | 1 | 2014 | 5079 | 0.170 |
Why?
|
Laser Coagulation | 1 | 2022 | 330 | 0.170 |
Why?
|
Visual Field Tests | 1 | 2021 | 411 | 0.160 |
Why?
|
Post-Concussion Syndrome | 1 | 2021 | 243 | 0.160 |
Why?
|
Tomography, Optical Coherence | 2 | 2021 | 2917 | 0.120 |
Why?
|
Microscopy, Acoustic | 1 | 2014 | 47 | 0.120 |
Why?
|
Spatial Behavior | 1 | 2014 | 88 | 0.120 |
Why?
|
Central Serous Chorioretinopathy | 1 | 2014 | 27 | 0.120 |
Why?
|
Risk Assessment | 1 | 2014 | 23996 | 0.110 |
Why?
|
Gestational Age | 1 | 2022 | 3577 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 1 | 2022 | 2048 | 0.100 |
Why?
|
Athletic Injuries | 1 | 2021 | 1216 | 0.090 |
Why?
|
Macular Edema | 1 | 2014 | 374 | 0.090 |
Why?
|
Brain Concussion | 1 | 2021 | 1404 | 0.090 |
Why?
|
Disease Progression | 1 | 2024 | 13510 | 0.070 |
Why?
|
Adolescent | 4 | 2024 | 88323 | 0.070 |
Why?
|
Retrospective Studies | 3 | 2022 | 80646 | 0.070 |
Why?
|
Child | 3 | 2024 | 80157 | 0.070 |
Why?
|
Male | 8 | 2024 | 360841 | 0.060 |
Why?
|
Humans | 12 | 2024 | 761578 | 0.060 |
Why?
|
Diabetic Retinopathy | 1 | 2014 | 1274 | 0.060 |
Why?
|
Child, Preschool | 2 | 2024 | 42231 | 0.060 |
Why?
|
Atropine | 1 | 2024 | 244 | 0.060 |
Why?
|
Female | 7 | 2024 | 392688 | 0.060 |
Why?
|
Ophthalmic Solutions | 1 | 2024 | 313 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2022 | 26198 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8830 | 0.050 |
Why?
|
Middle Aged | 5 | 2015 | 220917 | 0.040 |
Why?
|
Infant | 1 | 2022 | 36193 | 0.040 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 26127 | 0.040 |
Why?
|
Prospective Studies | 1 | 2024 | 54423 | 0.040 |
Why?
|
Cohort Studies | 1 | 2022 | 41493 | 0.040 |
Why?
|
Aged, 80 and over | 2 | 2014 | 58983 | 0.040 |
Why?
|
Aged | 3 | 2014 | 169308 | 0.030 |
Why?
|
Incidence | 1 | 2014 | 21355 | 0.030 |
Why?
|
Prognosis | 1 | 2014 | 29629 | 0.030 |
Why?
|
Young Adult | 2 | 2015 | 59254 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2024 | 12341 | 0.020 |
Why?
|
Photic Stimulation | 1 | 2015 | 1987 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2021 | 7054 | 0.020 |
Why?
|
Risk Factors | 1 | 2014 | 74212 | 0.020 |
Why?
|
Adult | 2 | 2015 | 221200 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2024 | 39107 | 0.010 |
Why?
|
Time Factors | 1 | 2024 | 39970 | 0.010 |
Why?
|